Facets (new session)
Description
Metadata
Settings
owl:sameAs
Inference Rule:
b3s
b3sifp
dbprdf-label
facets
http://dbpedia.org/resource/inference/rules/dbpedia#
http://dbpedia.org/resource/inference/rules/opencyc#
http://dbpedia.org/resource/inference/rules/umbel#
http://dbpedia.org/resource/inference/rules/yago#
http://dbpedia.org/schema/property_rules#
http://www.ontologyportal.org/inference/rules/SUMO#
http://www.ontologyportal.org/inference/rules/WordNet#
http://www.w3.org/2002/07/owl#
ldp
oplweb
skos-trans
virtrdf-label
None
About:
Isolation of a human monoclonal antibody specific for the receptor binding domain of SARS-CoV-2 using a competitive phage biopanning strategy
Goto
Sponge
NotDistinct
Permalink
An Entity of Type :
schema:ScholarlyArticle
, within Data Space :
covidontheweb.inria.fr
associated with source
document(s)
Type:
Academic Article
research paper
schema:ScholarlyArticle
New Facet based on Instances of this Class
Attributes
Values
type
Academic Article
research paper
schema:ScholarlyArticle
isDefinedBy
Covid-on-the-Web dataset
has title
Isolation of a human monoclonal antibody specific for the receptor binding domain of SARS-CoV-2 using a competitive phage biopanning strategy
Creator
Liu, Bin
Zhang, Tao
Zeng, Xin
Lin, Jing
Du, Jianhua
Kong, Yang
Li, Lingfang
Li, Xinlei
Liu, Jianghai
Xiao, Huahong
Zeng, Shunze
Zhang, Shelin
Source
PMC
abstract
The infection of the novel coronavirus SARS-CoV-2 has caused more than 200,000 deaths, but no vaccine or therapeutic monoclonal antibody is currently available. SARS-CoV-2 relies on its spike protein, in particular the receptor binding domain (RBD), to bind human cell receptor angiotensin-converting enzyme 2 (ACE2) for viral entry, and thus targeting RBD holds the promise for preventing SARS-CoV-2 infection. In this work, a competitive biopanning strategy of a phage display antibody library was applied to screen blocking antibodies against RBD. High-affinity antibodies were enriched after the first round using a standard panning process in which RBD-His was immobilized as a bait. At the next two rounds, immobilized ACE2-Fc and free RBD-His were mixed with the enriched phage antibodies. Antibodies binding to RBD at epitopes different from ACE2-binding site were captured by the immobilized ACE2-Fc, forming a “sandwich” complex. Only antibodies competed with ACE2 can bind to the free RBD-His in the supernatant and be subsequently separated by the Ni-NTA magnetic beads. Top 1 lead from the competitive biopanning of our synthetic antibody library, Lib AB1, was produced as the full-length IgG1 format. It was proved to competitively block the binding of RBD to ACE2 and potently inhibit SARS-CoV-2 pseudovirus infection with IC(50) values of 12 nM. Nevertheless, top 1 lead from the standard biopanning can only bind to RBD in vitro, but not have the blocking or neutralization activity. Our strategy can efficiently isolate the blocking antibodies of RBD, and it would speed up the discovery of neutralizing antibodies against SARS-CoV-2.
has issue date
2020-04-30
(
xsd:dateTime
)
bibo:doi
10.1093/abt/tbaa008
has license
cc-by-nc
sha1sum (hex)
9be4ef774dcde18cd989275e5e1c130f2c18af55
schema:url
https://doi.org/10.1093/abt/tbaa008
resource representing a document's title
Isolation of a human monoclonal antibody specific for the receptor binding domain of SARS-CoV-2 using a competitive phage biopanning strategy
has PubMed Central identifier
PMC7197610
schema:publication
Antib Ther
resource representing a document's body
covid:9be4ef774dcde18cd989275e5e1c130f2c18af55#body_text
is
schema:about
of
named entity 'human'
named entity 'receptor'
named entity 'INTERACTION'
named entity 'BINDS'
named entity 'AFFINITY'
named entity 'enzyme'
named entity 'inhibits'
named entity 'SARS-CoV-2'
named entity 'competitive'
named entity 'biopanning'
named entity 'phage'
named entity 'human monoclonal antibody'
named entity 'epitope mapping'
named entity 'biopanning'
named entity 'antibodies'
named entity 'ACE2'
named entity 'steric clash'
named entity 'phages'
named entity 'SARS-CoV-2'
named entity 'ACE2'
named entity 'inoculated'
named entity 'supernatant'
named entity 'coronavirus'
named entity 'Coronavirus'
named entity 'antibodies'
named entity 'ACE2'
named entity 'reproductive number'
named entity 'structural analysis'
named entity 'antibody'
named entity 'pseudovirus'
named entity 'SARS-CoV'
named entity 'antibody'
named entity 'SARS-CoV-2'
named entity 'SARS-CoV'
named entity 'biopanning'
named entity 'antibody'
named entity 'SARS-CoV-2'
named entity 'biopanning'
named entity 'high-affinity'
named entity 'RBD'
named entity 'supernatant'
named entity 'phage'
named entity 'protein'
named entity 'positive control'
named entity 'RBD'
named entity 'protein'
named entity 'negative control'
named entity 'mAbs'
named entity 'biopanning'
named entity 'conformation'
named entity 'Microsoft Office Excel'
named entity 'supernatant'
named entity 'SARS-CoV-2'
named entity 'SARS-CoV-2'
named entity 'phage display'
named entity 'Hela'
named entity 'RBD'
named entity 'biopanning'
named entity 'cell membrane'
named entity 'COVID'
named entity 'structural homology'
named entity 'cross-reactivity'
named entity 'global pandemic'
named entity 'SARS-CoV-2'
named entity 'phages'
named entity 'homology'
named entity 'ACE2'
named entity 'RBD'
named entity 'RBD'
named entity 'RBD'
named entity 'SARS-CoV-2'
named entity 'ACE2'
◂◂ First
◂ Prev
Next ▸
Last ▸▸
Page 1 of 5
Go
Faceted Search & Find service v1.13.91 as of Mar 24 2020
Alternative Linked Data Documents:
Sponger
|
ODE
Content Formats:
RDF
ODATA
Microdata
About
OpenLink Virtuoso
version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software